Peter Kremsner from the University Hospital in Tuebingen which is running the trial told Reuters the low efficacy is "very likely due to the dose".
With just 12 micrograms of mRNA per dose, the company has been seeking to position itself as a low-dose alternative to BioNTech and Moderna's established shots with 30 and 100 micrograms per shot, respectively. However, the interim trial analysis goes some way to challenging the expectation, which was previously reflected in the company's share price, that all mRNA vaccines are similar. The news wiped as much as 52% off the company's value on Thursday.CureVac said on Wednesday that new variants had proved a headwind, but data from BioNTech and Moderna have, however, so far suggested only somewhat weaker protection against new variants.
I wouldn't and won't ever know about that xxx
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
How a low-profile Senate vote could spell trouble for Big TechThe senate confirmed Lina Khan, an established critic of tech companies' market power, to a seat on the Federal Trade Commission by a 69-28 margin, picking up support from a bipartisan coalition favoring more aggressive action against Big Tech. Couple of months ago I came across a recommendation about GeorgeLinf32 wealth how he helped investors to earn lots of money with their investments. and I decided to give a trial with the little I have. Now my little has turned into something great which was not my expectation W sonaliranade A first small, albeit significant, step towards monitoring and reigning in of big tech. Congratulations linamkhan.
Source: NBCNews - 🏆 10. / 86 Read more »
Leslie Grace’s Guide to Low-Key Glam Makeup and Second-Day BlowoutsWatch IntheHeights star Leslie Grace reveal her BeautySecrets, from false eyelashes to how she prolongs the lifespan of her blowout. i_Ditaly
Source: VogueRunway - 🏆 705. / 51 Read more »
CureVac shares tank 50% after preliminary data shows Covid vaccine is only 47% effectiveThe late-stage clinical trial found high prevalence of virus variants. Lmao They don’t even need to bother rolling it out at this point 47%?!
Source: CNBC - 🏆 12. / 72 Read more »
CureVac says its COVID vaccine was poor match against 29 COVID variants, as global case tally tops 177 millionThe global tally of confirmed cases of COVID-19 climbed above 177 million on Thursday, a day after disappointing news from CureVac with the German company... Oh no
Source: MarketWatch - 🏆 3. / 97 Read more »
CureVac’s pain may not yet have peakedCureVac’s , (5CV.DE) vaccine agony may have further to run. The German biotechnology company’s Frankfurt-listed shares halved on Thursday after the group revealed that its Covid-19 jab may be only 47% effective. That’s a major blow, but the bigger concern for investors is if CureVac’s so-called “messenger RNA” technology behind its cancer and rabies vaccines has flaws. veltcardio Acá se enteraron y van a pedir 6 millones de dosis 😆
Source: Reuters - 🏆 2. / 97 Read more »
Africa's Covid patients 'dying from lack of oxygen'Health agencies and medics tells the BBC of a growing crisis facing low-income African nations. They have all had the chance to develop their own industries but prefer to be corrupt and scrounge from other nations, if the will was there in the first place all these countries could be really profitable and stand on their own feet.
Source: bbchealth - 🏆 143. / 63 Read more »